Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva's US IUD Brings In $1.1bn For The Embattled Generics Firm

Executive Summary

Teva’s planned divestment of non-core assets in order to refocus the company after a troubled first-half has started with a contraceptive device.


Related Content

Device/Diagnostics Quarterly Deal-Making Statistics, Q3 2017
Teva Lands A CEO: Can Schultz Replicate Lundbeck Success?
Time Is Of The Essence As Teva Considers European Assets Bids
Teva SOS: Troubled Drug Maker Seeks Audacious Captain To Take The Wheel


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts